Google's Verily Makes Clinical Trials Pitch With Big Pharma Pacts
Executive Summary
Verily has kept a low profile since it was set up in 2015 but deals with Novartis, Otsuka, Pfizer and Sanofi reveal the data management giant's ambitions to become a major player in the lucrative clinical studies space.
You may also be interested in...
Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
How Novartis Is Making SENSE Of Clinical Data In Digital Age
The Swiss major has been showcasing its Nerve Live data analytics platform, where staff stationed at its SENSE operations center in Basel can monitor 500 or so clinical studies to predict - and stop - potential delays.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.